Drug intelligence / Profile preview

OK99

Development stage: Phase 1
Lead developer: Celavie Biosciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraputaminal

Overview

OK99 is a human allogeneic stem cell therapy developed by Celavie Bioscences, LLC. It is being investigated for the treatment of severe Parkinson's Disease. The therapy is designed to address the underlying pathology of the disease by replacing damaged or destroyed cells in the brain and/or stimulating the patient's brain to repair itself.

Other names: Human fetal stem cellsUndifferentiated human fetal stem cellsAllogeneic pluripotent stem cells

Beyond the preview

Go deeper on OK99.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OK99.

Explore the full profile